GreenLight Biosciences and Germains Seed Technology Partner to Explore Development of World’s First dsRNA Seed Treatment to Control Pests

BOSTON, January 31, 2022 – GreenLight Biosciences and Germains Seed Technology, an industry leader in seed treatment technologies, today announced a research partnership agreement that could lead to the first commercial use of RNA as a seed treatment to control crop diseases and offer options to farmers looking for innovative solutions.

Through the partnership, the two companies will explore synergies between Germains’ seed priming and coating technologies and GreenLight’s dsRNA expertise and ability to cost-effectively scale manufacturing to protect vegetable crops. In October 2021, GreenLight announced that the company had achieved, for the first time ever, effective field control of fungal pathogens using double-stranded RNA. 

“Farmers and agribusinesses are looking for effective, affordable and sustainable alternatives to traditional crop protection, particularly as environmental and market pressures to do so continue to increase,” said Mark Singleton, GreenLight’s Senior Vice President of Technology & External Innovation.

“We’re excited to work with the leading seed treatment experts at Germains to develop potential additional applications for RNA to address those challenges,” he said. “Our ability to produce large-scale commercial quantities of RNA at low cost and with high quality in our Rochester, New York, facility means we are well-positioned to quickly commercialize and scale new products in our pipeline.”

“Germains Seed Technology has been a leader in the international seed industry for 150 years, and our strength as a company is rooted in our commitment to innovation as we seek to maximize nature’s potential and meet customers’ needs,” said Dale Krolikowski, Germains’ Head of Business Development and Research.

“We believe this new partnership with GreenLight Biosciences has the potential to build a new generation of products that do just that. RNA technology presents enormous potential for the seed treatment industry, and we are thrilled to be working with the innovators at GreenLight to push the industry forward.” 

GreenLight’s technology complements Germains’ Health brand, which has delivered several novel seed treatments over the last few years, including Ultim^®-ST organic protection against Pythium. The partnership will allow Germains to provide further innovation to customers as the company works to address seed-borne and soil-borne pathogens, which continue to cause dramatic crop losses every year.

The fast-growing seed treatment market is valued at approximately $6.5 billion, with an estimated growth rate between 10 and 12 percent annually. If successful, this partnership would mark a key addition to GreenLight’s portfolio and intended pipeline of agricultural products, as well as a critical addition to Germains’ offerings of innovative seed treatments and grower solutions. 

In 2022, GreenLight anticipates receiving U.S. regulatory approval of its RNA-based product for controlling the Colorado potato beetle and intends to submit its honeybee health solution to the U.S. Environmental Protection Agency. The company has seven agricultural products in development with an addressable market of $6 billion that it plans to launch by 2026.

About GreenLight

Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. For more information, visit https://live-greenlightbiosciences.pantheonsite.io/

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).

About Germains Seed Technology

Celebrating 150 years of serving the agriculture industry, Germains has sales offices and research facilities in North America, the United Kingdom, and Europe. Germains Seed Technology is committed to delivering industry-leading innovative seed technologies for sugar beet, vegetable, and field crops for seed producers, dealers, and growers globally. For more information, go to http://germains.com. 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:

Thomas Crampton

SVP & Head of Corporate Affairs, GreenLight Biosciences

[email protected]

+44 7826 995794 +1-914-202-2762